Marina Biotech (MRNA) 0.5920 $MRNA
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics
Marketwired - Thu Dec 18, 7:01AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014
Marketwired - Tue Dec 09, 7:02AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, reported that a number of patients with relapsed or refractory Non-Hodgkin's Lymphoma treated with its first DNAi(R)-based therapeutic, PNT2258, achieved meaningful therapeutic outcomes and continue to exhibit durable clinical responses. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES(R) delivery technology.
Market Maker Surveillance Report. BEBE, VSR, APT, LAKE, ECSL, MRNA, Winning Stocks With Lowest Price Friction For Tuesday, November 25th 2014
M2 - Wed Nov 26, 3:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4467 companies with "abnormal" market making, 2411 companies with positive Friction Factors and 2537 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. bebe stores inc (NASDAQ:BEBE), Versar Inc (NYSE:VSR), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), ECARE SOLUTIONS INC (OTC:ECSL), MARINA BIOTECH INC (OTC:MRNA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BEBE: 3.90 (+0.01), APT: 2.88 (+0.17), LAKE: 10.18 (+0.89), VSR: 3.42 (-0.02)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 3.65 (+0.32), ISIS: 63.86 (-0.43), DRNA: 21.30 (-0.06), ALNY: 95.54 (+1.67), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), TKMR: 21.45 (-0.22), RGLS: 16.85 (-0.13)
Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST
ROSG: 3.65 (+0.32), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-in-Class microRNA-34 Mimic
Marketwired - Thu Nov 20, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its partner, Mirna Therapeutics, presented interim safety and preliminary efficacy data from a multicenter, open-label Phase 1 clinical trial of MRX34. MRX34 is a microRNA34 mimic formulated in the Company's SMARTICLES(R) delivery technology. The data show that MRX34 has a manageable safety profile in patients with advanced primary liver cancer (hepatocellular carcinoma), other solid tumors with liver metastasis, and hematological malignancies. A maximum tolerated dose (MTD) was established at 110 mg/m2 for MRX34 administered twice weekly for three weeks followed by one week off. Dose escalation is on-going for a second dosing regimen wherein MRX34 is administered daily for five consecutive days followed by two weeks off. While this Phase 1 study is intended to investigate safety, tolerability, pharmacokinetics, and dosing regimens, treatment with MRX34 has provided early signals of clinical activity in advanced cancer patients with primary liver, neuroendocrine, colorectal and small cell lung cancers, as well as diffuse large B-cell lymphoma.
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Marketwired - Wed Nov 19, 3:10PM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
ROSG: 3.65 (+0.32)
Marina Biotech Announces Third Quarter 2014 Financial Results
Marketwired - Mon Nov 17, 6:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended September 30, 2014.
Prosensa begins FDA submission process for DMD drug candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 2:37PM CDT
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors
Marketwire - Tue Sep 16, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that all five of the director nominees submitted to the company's stockholders for election at Marina Biotech's 2014 Annual Meeting of Stockholders held on September 15, 2014 in San Diego, CA were elected to serve as members of the company's board of directors. The director nominees included four incumbent directors -- J. Michael French, Stefan Loren, Ph.D., Joseph W. Ramelli and Philip C. Ranker -- as well as new board member Donald A. Williams. In addition to the election of all of the director nominees, the recommendations of the Board with respect to all five of the other items that were described in the proxy statement for consideration at the Annual Meeting also received sufficient stockholder support.
Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate
Marketwire - Thu Sep 11, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it had received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering the following delivery technologies: SMARTICLES(R) in Europe; TransKingdom RNA(TM) interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. These grants support a global intellectual property estate broadly covering the Company's biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S. and foreign patent applications.
Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences
Marketwire - Wed Sep 03, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.
Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
Marketwire - Wed Aug 20, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2012 and December 31, 2013, its Quarterly Reports on Form 10-Q for the first three quarters of the 2013 fiscal year, and its Quarterly Reports on Form 10-Q for the first and second fiscal quarters of 2014 over the past thirty days. In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
Marketwire - Thu Jun 12, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company's licensee, Mirna Therapeutics, has reported that Mirna enrolled the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34. MRX34 is Mirna's lead product candidate and first microRNA mimic in human clinical trials in the oncology space. Under terms of the license agreement, Mirna has full responsibility for the development and commercialization of any products which arise during the license period, and Marina Biotech could receive up to $60 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics
Marketwired - Thu Dec 18, 7:01AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014
Marketwired - Tue Dec 09, 7:02AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, reported that a number of patients with relapsed or refractory Non-Hodgkin's Lymphoma treated with its first DNAi(R)-based therapeutic, PNT2258, achieved meaningful therapeutic outcomes and continue to exhibit durable clinical responses. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES(R) delivery technology.
Market Maker Surveillance Report. BEBE, VSR, APT, LAKE, ECSL, MRNA, Winning Stocks With Lowest Price Friction For Tuesday, November 25th 2014
M2 - Wed Nov 26, 3:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4467 companies with "abnormal" market making, 2411 companies with positive Friction Factors and 2537 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. bebe stores inc (NASDAQ:BEBE), Versar Inc (NYSE:VSR), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), ECARE SOLUTIONS INC (OTC:ECSL), MARINA BIOTECH INC (OTC:MRNA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BEBE: 3.90 (+0.01), APT: 2.88 (+0.17), LAKE: 10.18 (+0.89), VSR: 3.42 (-0.02)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 3.65 (+0.32), ISIS: 63.86 (-0.43), DRNA: 21.30 (-0.06), ALNY: 95.54 (+1.67), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), TKMR: 21.45 (-0.22), RGLS: 16.85 (-0.13)
Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST
ROSG: 3.65 (+0.32), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-in-Class microRNA-34 Mimic
Marketwired - Thu Nov 20, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its partner, Mirna Therapeutics, presented interim safety and preliminary efficacy data from a multicenter, open-label Phase 1 clinical trial of MRX34. MRX34 is a microRNA34 mimic formulated in the Company's SMARTICLES(R) delivery technology. The data show that MRX34 has a manageable safety profile in patients with advanced primary liver cancer (hepatocellular carcinoma), other solid tumors with liver metastasis, and hematological malignancies. A maximum tolerated dose (MTD) was established at 110 mg/m2 for MRX34 administered twice weekly for three weeks followed by one week off. Dose escalation is on-going for a second dosing regimen wherein MRX34 is administered daily for five consecutive days followed by two weeks off. While this Phase 1 study is intended to investigate safety, tolerability, pharmacokinetics, and dosing regimens, treatment with MRX34 has provided early signals of clinical activity in advanced cancer patients with primary liver, neuroendocrine, colorectal and small cell lung cancers, as well as diffuse large B-cell lymphoma.
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Marketwired - Wed Nov 19, 3:10PM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
ROSG: 3.65 (+0.32)
Marina Biotech Announces Third Quarter 2014 Financial Results
Marketwired - Mon Nov 17, 6:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended September 30, 2014.
Prosensa begins FDA submission process for DMD drug candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 2:37PM CDT
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors
Marketwire - Tue Sep 16, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that all five of the director nominees submitted to the company's stockholders for election at Marina Biotech's 2014 Annual Meeting of Stockholders held on September 15, 2014 in San Diego, CA were elected to serve as members of the company's board of directors. The director nominees included four incumbent directors -- J. Michael French, Stefan Loren, Ph.D., Joseph W. Ramelli and Philip C. Ranker -- as well as new board member Donald A. Williams. In addition to the election of all of the director nominees, the recommendations of the Board with respect to all five of the other items that were described in the proxy statement for consideration at the Annual Meeting also received sufficient stockholder support.
Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate
Marketwire - Thu Sep 11, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it had received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering the following delivery technologies: SMARTICLES(R) in Europe; TransKingdom RNA(TM) interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. These grants support a global intellectual property estate broadly covering the Company's biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S. and foreign patent applications.
Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences
Marketwire - Wed Sep 03, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.
Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
Marketwire - Wed Aug 20, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2012 and December 31, 2013, its Quarterly Reports on Form 10-Q for the first three quarters of the 2013 fiscal year, and its Quarterly Reports on Form 10-Q for the first and second fiscal quarters of 2014 over the past thirty days. In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
Marketwire - Thu Jun 12, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company's licensee, Mirna Therapeutics, has reported that Mirna enrolled the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34. MRX34 is Mirna's lead product candidate and first microRNA mimic in human clinical trials in the oncology space. Under terms of the license agreement, Mirna has full responsibility for the development and commercialization of any products which arise during the license period, and Marina Biotech could receive up to $60 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.
